Dendritic cell vaccine for multiple myeloma in remission
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help keep multiple myeloma from coming back. It's for people whose cancer is in very good remission after other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma or plasmacytoma (a related tumor of the plasma cells).
- Your cancer has responded very well to previous treatments—meaning it's either in very good partial remission or complete remission (almost gone or not detectable).
- You are expected to live at least 12 more weeks.
- You have veins that can be used for blood draws or apheresis (a procedure to collect cells).
- You are not pregnant, not breastfeeding, and do not have an active uncontrolled infection, HIV, or active hepatitis B or C.
- You are not taking steroids by mouth or IV (except inhaled steroids for breathing problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (O&D-001) for multiple myeloma that has returned or not responded to previous treatments. It targets specific markers on myeloma cells (BCMA or GPRC5D) and aims to shrink the cancer.
This trial tests a new kind of immunotherapy that uses your own immune cells, called CAR-T cells, to target two specific markers (BCMA and GPRC5D) found on myeloma cells. It's for people whose multiple myeloma has come back or stopped responding to earlier treatments.
This trial tests a new type of immunotherapy called Multi-CAR T cells for people with multiple myeloma that has come back or not responded to other treatments. It aims to see if these specially engineered cells can better fight the cancer.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) mixed with myeloma cells, given together with a drug called elranatamab. It is for people with multiple myeloma that has not responded to at least three prior treatments.
This trial tests whether a personalized vaccine (DC/MM fusion) given after standard CAR-T cell therapy can help prevent the cancer from coming back. It is for people with multiple myeloma that has returned or not responded to treatment.
This trial tests a combination of teclistamab (an immunotherapy) and your own immune cells to treat multiple myeloma that has come back or stopped responding to prior treatments. It is for people who have had 1 or 2 prior lines of therapy and have not received a BCMA-targeted treatment before.
Hear when a new Multiple Myeloma or Plasmacytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.